EEG-ERP Correlates of Cognitive Dysfunction in Polycystic Ovarian Syndrome

Pterostilbene Ameliorates Cognitive Impairment in Polycystic Ovary Syndrome Rat Model through Improving Insulin Resistance via the IRS-1/PI3K/Akt/GSK-3β Pathway: A Comparative Study with Metformin

Polycystic ovary syndrome (PCOS) is an intricate endocrine disorder that targets millions of women globally. Recent research has drawn attention to its association with cognitive impairment and Alzheimer's disease (AD) risk, yet the exact mechanism remains elusive. This study aimed to explore the potential role of PCOS-associated insulin resistance (IR) and inflammation in linking PCOS to AD pathogenesis. It additionally investigated the therapeutic merits of pterostilbene (PTS) in ameliorating PCOS and associated cognitive deficits in comparison to metformin (MET). Rats were divided into five groups; vehicle group, PTS group [30 mg/kg, per os (p.o.) for 13 days], and the remaining three groups received letrozole (1 mg/kg, p.o. for 21 days) to represent the PCOS, PCOS + MET (300 mg/kg, p.o. for 13 days), and PCOS + PTS groups, respectively. Behavioral tests were conducted, along with a histopathological investigation of brains and ovaries. Assessment of serum hormonal profile and hippocampal IRS-1/PI3K/AKT/GSK-3β insulin signaling pathway components were performed. PTS rats exhibited improved insulin sensitivity and hormonal profile, besides enhanced neurobehavioral tests performance and histopathological findings. These effects may be attributed to modulation of the IRS-1/PI3K/AKT/GSK-3β pathway, reducing GSK-3β activity, and mitigating Tau hyperphosphorylation and Aβ accumulation in the brain. Likewise, PTS attenuated nuclear factor kappa B-mediated inflammation and reversed AChE elevation, suggesting multifaceted neuroprotective effects. Comparatively, PTS showed outcomes similar to those of MET in most parameters. The obtained findings validated that dysregulated insulin signaling in PCOS rats detrimentally affects cognitive function, which is halted by PTS, unveiling the potential of PTS as a novel therapy for PCOS and related cognitive deficits.

Psychological symptoms and brain activity alterations in women with PCOS and their relation to the reduced quality of life: a narrative review

BACKGROUND

Polycystic ovary syndrome (PCOS) is the most common feminine endocrine disorder, characterized by androgen excess, ovulatory dysfunction, and polycystic ovarian morphology. The negative impact of symptoms on the quality of life (QoL) of patients is still not clear.

PURPOSE

The present review aimed at studying the impact of the symptoms, the psychological symptoms, and brain alterations in women with PCOS.

METHODS

A systematic search was undertaken for studies that assessed the impact of PCOS symptoms on QoL, psychological symptoms, and brain alterations in PCOS patients.

RESULTS

Most of the information about QoL came from psychometric studies, which used culture-based questionnaires. Alterations of sleep quality, body image, and mood disorders can negatively affect the QoL of the patients. Sexual satisfaction and desire were affected by PCOS. Brain imaging studies showed functional alterations that are associated with impairments of visuospatial working memory, episodic and verbal memory, attention, and executive function.

CONCLUSIONS

Several factors can negatively influence the quality of life of the patients, and they are directly related to hyperandrogenism and the risk of infertility. In particular, obesity, hirsutism, acne, and the fear of infertility can have a direct impact on self-esteem and sexual function. Metabolic and psychiatric comorbidities, such as mood, anxiety, and eating disorders, can affect the well-being of the patients. Moreover, specific cognitive alterations, such as impairments in attention and memory, can limit PCOS patients in a series of aspects of daily life.

Contingent negative variation as an evaluation indicator of neurocognitive disorder after traumatic brain injury

Introduction

Neurocognitive disorders are commonly observed in patients suffering from traumatic brain injury (TBI). Methods to assess neurocognitive disorders have thus drawn the general attention of the public, especially electrophysiology parameter such as contingent negative variation (CNV), which has been given more emphasis as a neurophysiological marker in event-related potentials (ERPs) for diagnosing a neurocognitive disorder and assessing its severity. The present study focused on the correlations between CNV parameters and levels of daily living activities and social function to explore the potential of CNV as an objective assessment tool.

Methods

Thirty-one patients with a diagnosis of neurocognitive disorder after a TBI according to ICD-10 were enrolled as the patient group, and 24 matched healthy volunteers were enrolled as the control group. The activity of daily living scale, functional activities questionnaire, social disability screening schedule, and scale of personality change following TBI were used to assess daily living activity and social function.

Results

The scale scores in patients were significantly higher than those in controls. Maximum amplitudes before S2 and during the post-imperative negative variation (PINV) period were also significantly higher in the patient group compared to the control group and were positively correlated with four scale scores. The duration of PINV at Fz and Cz was significantly shorter in the patient group than in the control group. The CNV return to baseline from a positive wave at electrode Fz and Cz occurred significantly earlier in the control group than in the patient group, while at Pz, the result showed the opposite.

Conclusion

Lower amplitudes of CNV were associated with more severe neurocognitive disorder and greater impairments in daily life abilities and social function. The duration of PINV and the latency of returning to baseline from a positive wave were correlated with the neurocognitive disorder to some extent. CNV could be used as an objective, electrophysiology-based parameter for evaluating the severity of the neurocognitive disorder and personality changes after TBI.